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Viral infection compromises specific organelles of the cell and readdresses its
functional resources to satisfy the needs of the invading body. Around 70% of
the coronavirus positive-sense single-stranded RNA encodes proteins involved
in replication, and these viruses essentially take over the biosynthetic and
transport mechanisms to ensure the efficient replication of their genome and
trafficking of their virions. Some coronaviruses encode genes for ion-channel
proteins – the envelope protein E (orf4a), orf3a and orf8 – which they
successfully employ to take control of the endoplasmic reticulum–Golgi
complex intermediate compartment or ERGIC. The E protein, which is one
of the four structural proteins of SARS-CoV-2 and other coronaviruses,
assembles its transmembrane protomers into homopentameric channels with
mild cationic selectivity. Orf3a forms homodimers and homotetramers. Both
carry a PDZ-binding domain, lending them the versatility to interact with more
than 400 target proteins in infected host cells. Orf8 is a very short 29-amino-acid
single-passage transmembrane peptide that forms cation-selective channels
when assembled in lipid bilayers. This review addresses the contribution of
biophysical and structural biology approaches that unravel different facets of
coronavirus ion channels, their effects on the cellular machinery of infected cells
and some structure–functional correlations with ion channels of higher
organisms.
1. Introduction and background
Only a few weeks after the outbreak of the coronavirus
disease 2019 (COVID-19) pandemic, biophysical studies
produced atomic scale data on key structures of the causative
agent, Severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). This attests to a very positive reaction by the
scientific community in tackling a biomedical problem of
unprecedented proportions. Structural biology was the first
scientific discipline to apply powerful biophysical methods and
produce solid data in attempts to understand the pathogenesis
of the disease and search for its biomedical remediation
(Barrantes, 2021).
From a genomic perspective, SARS-CoV-2 belongs to the
same category of positive-strand RNA [(+)RNA] viruses as
hepatitis C, Chikingunya and Zika viruses. From a taxonomic
viewpoint, SARS-CoV-2 belongs to the subfamily Corona-
virinae in the Coronaviridae family that comprises four
genera: Alphacoronavirus, Betacoronavirus, Gamma-
coronavirus and Deltacoronavirus (González et al., 2003;
Letko et al., 2018). Coronaviruses (CoVs) pack between 26
and 32 kilobases of single-stranded positive-sense RNA inside
their envelope. CoVs were first identified in the late 1970s in
electron microscopy (EM) studies of negatively stained
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specimens and their name was coined due to the fuzzy solar
corona appearance surrounding the spherical virion envelope
(Almeida & Tyrrell, 1967), which we now know stems from the
coverage of the envelope with copies of the spike (S) protein,
one of the four structural proteins in these viruses. The highly
pathogenic avian bronchitis virus was discovered in the early
1930s (Estola, 1970), but it was not known until decades later
that it belonged to the Gammacoronavirus genus of the
Coronaviridae (González et al., 2003). CoVs cause mild to
severe respiratory, enteric and neurological diseases in species
ranging from avians to mammals (Lai & Cavanagh, 1997; Cui
et al., 2019; Woo et al., 2014).
The first study to identify a CoV infection in humans is
attributed to Hartley and coworkers, who found antibodies to
Mouse hepatitis virus (MHV) in the serum of affected patients
(Hartley et al., 1964). A total of seven human CoVs (HCoVs)
have since been identified. HCoV-OC43, HCoV-293, HCoV-
NL63 and HKU1-CoV generally cause mild respiratory
diseases, mainly forms of the common cold, along with other
viruses with tropism for the nasal and upper respiratory tract
mucosae. A second category of HCoVs comprises the highly
pathogenic SARS-CoVandMERS-CoV, the etiological agents
of severe acute respiratory syndrome (SARS) and Middle
East respiratory syndrome (MERS), responsible for the
epidemics in 2003 and 2012, respectively, and SARS-CoV-2,
the causative agent of the current COVID-19 pandemic.
The structural–functional correlations of SARS-CoV-2 ion-
channel proteins and their comparison with those of other
pathogenic CoVs have still not been fully characterized. This
is an area that needs investigation, particularly because these
proteins are purported to fulfil a role in infected cells, with
possible implications for interventions that interfere with viral
replication. This short review discusses the topic of ion-
channel-forming protein structures in CoVs in general and in
SARS-CoV-2 in particular, in an attempt to put the subject in
perspective both from molecular biology and phylogenetic
standpoints, and to draw attention to their potential as targets
for prophylactic and/or therapeutic interventions.
Comprehensive reviews of the biological and evolutionary
(Li et al., 2020), epidemiological (Su et al., 2016), clinical
(Richardson et al., 2020; Guan et al., 2020), microbiological
(Fung & Liu, 2019) and physicochemical (Scheller et al., 2020)
aspects and structure (Harrison, 2015; Tortorici & Veesler,
2019) of CoVs have appeared. The reader is also referred to
the reviews on the recent contribution of biophysics and
structural biology to current advances in COVID-19
(Barrantes, 2021) and the new possibilities for repurposed
drugs (Barrantes, 2020; Cavasotto & Di Filippo, 2021; Cava-
sotto et al., 2021) in handling the current pandemic.
2. Overall structure of CoVs
A common characteristic of members of the Coronaviridae is
the spiky appearance of the capsid (Neuman et al., 2006;
Neuman & Buchmeier, 2016; Wrapp et al., 2020). Contem-
porary cryo-EM images of the SARS-CoV-2 virion isolated
from the supernatant of infected cells show roughly spherical
bodies with a diameter of 91 11 nm (Ke et al., 2020), i.e. very
similar to other CoVs. Around 70% of the SARS-CoV-2
genome encodes proteins involved in RNA replication, with
the rest of the genome coding for structural and nonstructural
proteins. Besides the aforementioned S protein, CoVs have
three additional structural proteins, the nucleocapsid (N),
envelope (E) and membrane (M) proteins, 16 nonstructural
proteins and eight open reading frame (ORF) accessory
proteins (Dı́az, 2020).
N, the nucleocapsid protein, resides together with the RNA
genome in the ribonucleoprotein (RNP) core inside the
envelope. The N protein chaperones and protects the genomic
RNA. The M protein is an integral membrane glycoprotein
that contributes to adapting a region of the endoplasmic
reticulum–Golgi complex intermediate compartment (ERGIC)
membrane for virus assembly, thus defining the shape of the
viral envelope. When expressed alone, M accumulates in the
Golgi complex, but when expressed together with the E
protein, virus-like particles that are akin to authentic virions in
size and shape are assembled. This observation has led to the
idea that the M and E proteins constitute the minimal building
blocks for envelope formation (de Haan et al., 1999).
3. Viral ion-channel-forming proteins (viroporins)
In recent years, X-ray crystallography, transmission EM and
cryo-EM and nuclear magnetic resonance (NMR) techniques
have been applied to study the structures of some viral ion-
channel-forming proteins, also termed ‘viroporins’ (Liao et al.,
2006; Fischer & Hsu, 2011). The name, partly borrowed from
the bacterial -barrel porins, alludes to their ability to act as
ion-conducting pores in membrane bilayers, but in fact they
are more elaborate than this, exhibiting, for example, ion
selectivity. In silico studies using sequence-based molecular
modelling and homology modelling have provided comple-
mentary insights into these structures, finding common
architectures as well as diversity (see, for example, the review
by OuYang & Chou, 2014). Viroporins exhibit a low degree of
homology with ion channels of prokaryotic or eukaryotic
origin if one considers their overall structure, although their
transmembrane (TM) regions do bear some resemblance to
the corresponding regions of ion channels of higher organisms
(Fischer & Hsu, 2011), as analysed in the section on the
evolution of these proteins.
One of the first descriptions of ion-channel proteins in
viruses dates back to the early 1990s, when the matrix M2
protein of influenza virus was shown to confer ion perme-
ability on monovalent cations upon heterologous transfection
of Xenopus oocytes (Pinto et al., 1992). Subsequently, it was
demonstrated that this applies to influenza A and B viruses,
which also display permeability for protons, whereas the M2
proteins of influenza C and D viruses exhibit selectivity for
chloride ions, with some permeability for protons (see the
review by To & Torres, 2019).
Between the genes coding for the S protein and those for
other viral envelope genes, the CoV RNA genome contains a
locus that is conserved throughout the entire family. In the
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SARS-CoV genome, this region includes a complete or trun-
cated ORF (Zhang et al., 2014) containing the gene encoding
the E protein (also termed orf4a), orf3a and orf8a, three
proteins that form ion channels (Castaño-Rodriguez et al.,
2018). The CoVs MERS-CoV, HCoV-229E, HCoV-OC43 and
Porcine epidemic diarrhoea virus (PEDV) encode two such
ion channel-forming proteins (To et al., 2016; Castaño-
Rodriguez et al., 2018).
4. The small E protein (orf4a): pentameric structure and
membrane topology
At only 76–109 amino acids long, E is the smallest of the four
structural proteins of CoVs (Pervushin et al., 2009). It is an
integral membrane protein that is present in substoichiometric
quantities relative to other proteins embedded in the envelope
bilayer membrane; its precise functions are still not fully
known, except that its TM domain possesses ion-channel
properties and is probably involved in virion assembly (Siu et
al., 2008) and virion release from infected cells (reviewed in
Schoeman & Fielding, 2019). This has been documented for
MHV; its expression in Escherichia coli leads to increased
permeability, growth arrest and ultimately cell lysis (Madan et
al., 2005). The genomes of SARS-CoV (Liao et al., 2013),
MERS-CoV (Surya et al., 2015) and Infectious bronchitis virus
(IBV), a highly pathogenic avian infectious bronchitis virus
from the Gammacoronavirus genus (To et al., 2017), also code
for E proteins. E possesses a short hydrophilic amino-terminal
domain that is exposed to the cytoplasmic compartment of the
host cell (Maeda et al., 2001; Raamsman et al., 2000) and a
relatively long (25-amino-acid) TM domain. The TM domain
of the E protein is highly conserved among CoVs, with 91%
sequence identity and 98% sequence similarity (Cao et al.,
2020).
The exact topology of E relative to the membrane is still an
ongoing debate. Two amino acids are the main contributors to
the hydrophobicity of the TM domain: valine and leucine (Wu
et al., 2003). The TM domain is followed by a long hydrophilic
carboxy-terminus (Ye & Hogue, 2007) containing three
cysteine residues that have been suggested to play a role in the
association of E with the spike glycoprotein S (Wu et al., 2003).
Expression of the SARS-CoV E protein in Vero E6 cells
showed that it is N-glycosylated and that the two membrane-
spanning domains comprise amino-acid sequences 11–33 and
37–59, i.e. with a short loop between the two (Chen et al.,
2009). When analysing the TM region of E, one should
consider the two possible loci inhabited by this protein: (i) its
native viral envelope bilayer lipid membrane and (ii) the host-
cell intracellular membranes. In the former case, the E protein
has been proposed to traverse the viral lipid bilayer as a
single-passage helix (Raamsman et al., 2000) or a double-
passage helix (Raamsman et al., 2000; Maeda et al., 2001; Chen
et al., 2009). During the life cycle in the host cell, E is mainly
localized at the sites of viral replication, i.e. ER, Golgi and
ERGIC membranes. Recombinant CoVs lacking the E protein
show significantly lower viral titres/propagation-incompetent
progeny, suggesting the importance of E in virion production
and maturation (Schoeman & Fielding, 2019). E from IBV has
been reported to cross the Golgi membranes just once, with
the N-terminus facing the Golgi lumen and the C-terminus
facing the cytoplasm (Corse & Machamer, 2000), whereas E
from MHV is purported to traverse the lipid bilayer twice,
with both the N- and C-termini exposed to the cytoplasmic
compartment, which is topologically equivalent to the interior
of the virion (Maeda et al., 2001). A further proposal suggests
that the TM region of SARS-CoV E contains a 12-amino-acid
hairpin, which the authors propose is capable of deforming
lipid bilayers by increasing their curvature, a process that
would occur during virion budding from infected cells (Arbely
et al., 2004). The NMR data of Torres and coworkers (Li et al.,
2014) appeared to confirm the suggestion of a hairpin-like
structure formed by two helices joined by a less ordered
segment in the SARS-CoV E monomer. Subsequent work
from the same group indicated that E monomers possess only
one membrane-embedded -helical segment.
In terms of their oligomeric organization, a molecular-
modelling exercise led Torres and coworkers to suggest that
the TM segments of SARS-CoV E protein monomers adopt a
pentameric structure (Torres et al., 2005). NMR later led to
experimentally supported models of the SARS-CoV E protein
structure (Pervushin et al., 2009; Surya et al., 2018; Li et al.,
2014).
Fig. 1(a) shows a model of the SARS-CoV E protein
monomer obtained by solid-state NMR spectroscopy in
detergent–lipid micelles. The recombinant E protein was
expressed in bacteria and the lowest-energy structure was
calculated (Li et al., 2014). A long straight -helix, the
purported channel-forming domain, is joined through a flex-
ible linker domain (residues 46–54) to a short peripheral
C-terminal helix (residues 55–65) that bends obliquely with
respect to the longer helix and to the main axis of the ion-
channel pore (see Fig. 2) at the level of residue Tyr42.
Subsequent NMR studies in lauryl–myristoyl–phosphatidyl
glycerol (LMPG) micelles showed the monomer (residues
8–65) to consist of three segments, with the two -helices
penetrating the bilayer and an overall shape resembling a
fishing hook (Fig. 1b).
The homo-oligomer of the E protein is apparently self-
generated through specific amino-acid linear motifs of five
copies of the monomer, as suggested for the human corona-
virus HCoV-OC43 (Stodola et al., 2018). Fig. 2 draws a
comparison between the E proteins of the two related viruses
SARS-CoV and SARS-CoV-2. The model of the SARS-CoV
protein is derived from the NMR study in LMPG micelles
(Surya et al., 2018) and that of the SARS-CoV-2 E structure is
derived from NMR data at 2.4 Å resolution of the protein
reconstituted in ERGIC-mimetic liposomes containing
phosphocholine, phosphoethanolamine, phosphatidylinositol,
phosphoserine and cholesterol (Mandala et al., 2020). For
comparative purposes, liposomes made up of dimyristoylphos-
phocholine (DMPC):dimyristoylphosphoglycerol (DMPG)
membranes were employed. The NMR structures depart from
an ideal -helical geometry, apparently due to deformations
produced by three phenylalanine residues stacked between
topical reviews
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the helical chains lining the narrow pore. The blocker
hexamethylene amiloride binds to polar amino-acid residues
in the amino-terminal lumen of the pore.
The ring of TM segments forming the SARS-CoV-2 protein
E ion channel proper is also a pentameric bundle, but the
helices run perpendicular to the membrane plane, whereas in
the SARS-CoV E protein the homologous chains of the five
monomers are assembled into a pentameric body with an
inner ring of TM -helical segments (residues 15–45) tilted by
15 relative to the axis of the central ion-permeation
pathway (Fig. 2, top panel). The most striking difference
between the SARS-CoVand SARS-CoV-2 ion channels is the
simpler architecture of the latter, with a bundle of straight
-helical chains forming a single ring, contrasting with the two
helical rings in SARS-CoV. Since the two proteins share
92% sequence homology, the possibility arises that the
different structures of their membrane-associated regions are
partly due to the different media used in the NMR studies. A
pentameric structure has also been proposed for the E protein
of MERS-CoV (Surya et al., 2018).
In functional terms, early studies using planar lipid bilayers
showed that synthetic peptides corresponding to the SARS-
CoV E protein form ion channels in planar lipid bilayers with
selectivity for permeating monovalent cations over mono-
valent anions (Wilson et al., 2004). The E protein of SARS-
CoV was also found to modify the permeability of E. coli
membranes when expressed under reducing conditions, under
which E adopts a monomeric state, whereas nonreducing
conditions rendered the E protein in dimeric and homo-
trimeric forms (Liao et al., 2004). Reduction exposed two
cysteine residues essential for S—S bond-mediated oligomer-
ization; the changes in permeability were therefore attributed
to the exposure of the cysteine residues, although no distinc-
tion could be established between the direct and indirect
nature of the permeability changes using planar lipid bilayers
(Verdiá-Báguena et al., 2012). The E channel displays mono-
valent cation selectivity (Westerbeck & Machamer, 2019),
although it has also been reported to permeate Ca2+ (Nieto-
Torres et al., 2015). Ion conductance can be blocked by
hexamethylene amiloride, but not by amiloride, a drug that
inhibits the viral replication of some synthetic E proteins from
CoV (Pervushin et al., 2009). Based on the conductance
properties of E in planar bilayers (Wilson et al., 2004) or upon
transient expression in Xenopus oocytes and yeast systems, E
was suggested to form nonselective channels for monovalent
cations, although in the latter case Li+ partially reduced the
inward currents (Zhang et al., 2014). As observed with orf3a,
topical reviews
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Figure 1
NMR work by the Torres group led to early models of the monomeric
form of the SARS-CoV E protein in detergent–lipid micelles (Li et al.,
2014), showing two helical segments joined by a more disordered flexible
region flanked by amino-acid residues Tyr42 and Thr55 (a). The N-
terminal portion of the TM region [indicated by residue Val14 in (a)] is
purported to protrude into the lumenal side of the Golgi membranes, and
the C-terminal portion (here indicated by Asn64) to be partly exposed to
the cytoplasm. (b) Subsequent work showed the calculated E monomers
to consist of three -helical segments in LMPG micelles. The model
shown corresponds to an ensemble of ten calculated monomeric
structures, with the backbone rendered as a line representation.
Reproduced from Surya et al. (2018) with permission from Elsevier
Masson SAS under the Creative Commons Attribution licence (https://
creativecommons.org/licenses/by/4.0).
Figure 2
Comparative views of SARS-CoV and SARS-CoV-2 E protein models
derived from NMR data. The top panel shows the lowest-energy NMR-
derived structural model of the SARS-CoV E protein homopentamer
(PDB entry 5x29; Surya et al., 2018) in a lateral view (a) and an end-on
view (b). The bottom panel shows an NMR-derived model of the SARS-
CoV-2 E protein (PDB entry 7k3g; Mandala et al., 2020) in lateral (c) and
end-on (d) views. Notice that the ion-channel-lining helices of the SARS-
CoV E protein are more perpendicular to the membrane plane compared
with those of the SARS-CoV E protein. Images were produced using
CCP4mg (McNicholas et al., 2011).
electronic reprint
viral production diminished when protein E expression was
abrogated by applying siRNA to infected cells (Zhang et al.,
2014). The permeability properties of the new SARS-CoV-2 E
protein reconstituted in lipid bilayers with a composition
reported to mimic that of the ERGIC membrane has recently
appeared, showing that the ion channel displays a mild
cationic permeability. This can be blocked by the binding of
hexamethylene amiloride and amantadine to polar residues
shallowly located at the N-terminal lumen (Mandala et al.,
2020), thus confirming earlier work on the inhibitory action of
this drug on the viral channel (Pervushin et al., 2009).
In vitro experiments have shown that the lipid composition
of the host planar bilayer modulates the ion conductance of
the SARS-CoV E protein channel (Verdiá-Báguena et al.,
2012). Lipid charge was also found to play a role: the E protein
showed no cation selectivity in uncharged lipid membranes,
whereas negatively charged lipids resulted in mild cationic
selectivity (Verdiá-Báguena et al., 2012). The charge of the
ionizable groups of the E protein, as well as those from host
lipids such as diphytanoyl phosphatidylserine, was found to
modify channel conductance (Verdiá-Báguena et al., 2013).
The mutagenesis of amino-acid residues in the hydrophobic
TM domain of the E protein alters virus replication, which is
restored upon re-establishing the -helical structure (Ye &
Hogue, 2007). Helix-restored E protein is more sensitive to
treatment with hexamethylene amiloride, a drug that inhibits
the HIV ion channel Vpu and the E protein channel from
human HCoV-229 and rodent MHV, but not avian IBV
(Wilson et al., 2006). N15A and V25F mutations in the TM
region of the SARS-CoV E protein have been reported to
abrogate ion conductance (Verdiá-Báguena et al., 2012).
5. Orf3a
SARS-CoVorf3a is a much larger (274 amino acids) viral ion-
channel protein; it possesses three transmembrane domains.
Initially described as a structural protein unique to SARS-
CoV (Shen et al., 2005), it was subsequently reported that the
orf3a protein from the same virus, named U274 by these
authors, was a nonstructural protein that interacted with the
M, E and S structural proteins and orf7/U122 (Tan et al., 2004).
Recombinant SARS-CoV orf3a protein can form a homo-
tetrameric complex in orf3a-transfected cells (Lu et al., 2006;
Marquez-Miranda et al., 2020). A tetramer consisting of four
TM segments each has also been proposed using computa-
tional structure-prediction approaches (Wang et al., 2012).
When expressed in Xenopus oocytes, SARS-CoV orf3a is a
K+-sensitive channel that can efficiently be inhibited by Ba2+.
Similarly, ion-channel activity is generated upon transfection
of PEDV into Xenopus oocytes or yeast cells (Wang et al.,
2012). If cells are transfected with siRNA, thus suppressing
orf3a expression, infection with SARS-CoV replication is not
affected, but virion release is (Lu et al., 2006). Synthetic
peptides corresponding to each of the constituent TM
segments of orf3a were reconstituted into artificial lipid
bilayers. When the three peptides were assembled in a 1:1:1
mixture, ion-channel activity was observed, but either TM2 or
TM3 was required to induce currents; TM1 failed to do so.
Full-length orf3a expression showed weak cationic selectivity
and rectification (Chien et al., 2013).
Recently, SARS-CoV-2 orf3a was heterologously expressed
in Spodoptera frugiperda, reconstituted in liposomes, and
single-channel currents were recorded from excised patches
(Kern et al., 2020). Electrophysiologically, orf3a behaved as a
cation channel with a large single-channel conductance
(375 pA) with modest selectivity for Ca2+ and K+ over Na+.
The channel was not blocked by Ba2+ as was the case for the
SARS-CoV channel (Lu et al., 2006), nor was it inhibited by
the small drug emodin.
Kern and coworkers also employed cryo-EM to image the
apo form of the dimeric and tetrameric structures of orf3a
reconstituted in lipid nanodiscs. SARS-CoV-2 appears as a
homotetramer in which each monomer of the dimers contri-
butes three TM segments arranged in clockwise fashion,
making a total of six membrane-spanning domains per dimer
(Figs. 3a and 3b). Dimers are joined by a covalent S—S bond
distended between homologous Cys133 residues in each dimer
in the in silico model produced by Marquez-Miranda et al.
(2020) (Fig. 3b) or residues Trp131, Arg134, Lys136, His150,
Thr151, Asn152, Cys153 and Asp155 in the recent molecular-
modelling studies of Cavasotto and coworkers (Cavasotto &
Di Filippo, 2021; Cavasotto et al., 2021), bringing the total
number of TM helices to 12 and thus making this the largest
and most elaborate viral channel protein known to date. The
2.9 Å resolution cryo-EM structure of SARS-CoV-2 orf3a
(Kern et al., 2020) is very similar to that of the orf3a channel
structure of SARS-CoV (Lu et al., 2006), corroborating the
structural homology between several of the molecular
constituents of these two human pathogenic viruses from the
seven known to date. The all-helical TM region of the protein,
with a length of 40 Å, adopts a peculiar novel topography in
the lipid bilayer, whereas the cytosolic domain of the dimer
(30 Å) is formed by two -sandwiches (Fig. 3c). The novel
ion-channel structure possesses two potential ion pores, one in
each dimer; the walls of the ion channel proper are lined by
TM1 and TM2 of each monomer (Fig. 3c). The extracellular-
facing end of the ion channel exhibits a narrow bifurcated
pore that is reminiscent of the structure of vestibules in ion
channels of higher organisms. This outer portion of the
channel leads to a large polar cavity that is open to the cytosol.
The orf3a structure was captured by cryo-EM in a confor-
mation tentatively corresponding to a tetramer, and ascribed
by the authors to the closed or inactivated state (Kern et al.,
2020). A tubular electron-dense region potentially corre-
sponding to lipid acyl chains was partially resolved in between
the TM helices.
Interestingly, the molecular model from the cryo-EM data
of the orf 3a protein (PDB entry 6xdc; Marquez-Miranda et al.,
2020) disclosed the presence of chloride-binding sites inside
the ion-permeation pathway of SARS-CoV-2 orf3a.
6. Orf8a
Information on Orf8a is still very scanty. It is a cysteine-rich
29-amino-acid single-passage TM peptide present at least in
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SARS-CoV. Orf8a forms cation-selective ion channels with a
conductance close to 9 pS when assembled in lipid bilayers in
several putative oligomeric forms from tetramers to hexamers
(Chen et al., 2011). In silico calculations suggested that the first
topical reviews
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Figure 3
(a) Cryo-EMmap at 2.9 Å resolution of the full-length SARS-CoV-2 orf3a tetramer expressed in S. frugiperda and reconstituted in lipid nanodiscs (Kern
et al., 2020; EMDB entry EMD-22136). The backbone chain of one of the protomers docked into the cryo-EM map is outlined in burgundy. The
horizontal blue lines mark the limit between the upper TM domain and the lower cytoplasmic domain of the tetramer formed by multiple -sheets. (b)
Ribbon model of the SARS-CoV-2 orf3a tetramer derived from cryo-EM studies of the protein reconstituted in lipid nanodiscs. Each dimer possesses six
TM helices and a cytoplasmic domain with predominantly  secondary structure. The two dimers in the tetramer are purported to be covalently joined by
a disulfide bond formed by homologous Cys133 residues in each monomer (Marquez-Miranda et al., 2020). The molecular-modelling study by these
authors revealed the presence of a chloride ion site in the channel lumen. (c) Ribbon models of the SARS-CoV-2 orf3a dimer: an 70 Å cylinder in a
lateral view (left) and an end-on perspective as viewed from the extracellular side (right) derived from cryo-EM studies of the protein reconstituted in
lipid nanodiscs (Kern et al., 2020). Each protomer of the dimer has three helices that can fully traverse a lipid bilayer (40 Å) and a 30 Å-long
cytoplasmic domain with predominantly  secondary structure. The projection of the dimer onto the membrane plane is elliptic, with a major axis of
50 Å in width. The central ion path is flanked by TM segments 1 and 2, as seen in the centre of the end-on view. Images were produced using CCP4mg.
electronic reprint
22 amino acids of the single-TM domain of orf8a form a
homopentameric bundle (Hsu et al., 2015). The pentameric
bundle was also purported to exhibit weak cation selectivity
attributable to hydrophilic and hydrophobic stretches of
amino acids in the channel lumen.
7. The contribution of viral ion-channel proteins to
pathogenesis
SARS-CoV orf3a has been implicated in viral release,
inflammasome activation and cell death, and its deletion
reduces viral titres and morbidity in model systems (Freundt
et al., 2010). E downregulates the type-1 interferon (IFN)
receptor by inducing serine phosphorylation of the IFN
-receptor subunit 1 degradation motif and increasing
receptor ubiquitination (Minakshi et al., 2009).
The fact that a large proportion (>70%) of the CoV
genome, including that of SARS-CoV-2, is devoted to RNA
replication dictates the preferential intracellular tropism of
the virus to the biosynthetic machinery of the cell. Viral
proteins are initially synthesized in the endoplasmic reticulum
(ER), but most of the post-translational modifications occur at
the overlapping interface of the ER and the Golgi complex:
the ERGIC zone. Indeed, labelling the E protein with Rab-1, a
cytochemical marker of the intermediate compartment and
the ER, showed the accumulation of MHV CoV-A59 E
protein in the ERGIC region of the cell; electron microscopy
provided further evidence that E induces the formation of
tubular structures and induces curvature of the pre-Golgi
membranes, subsequently altering the Golgi-complex
membranes (Raamsman et al., 2000; Nieto-Torres et al., 2015).
E is purported to confer stability to the viral membrane and to
contribute to the later stages of the virion cycle in the infected
cell: the assembly and budding processes (Neuman et al.,
2011). E assembles by budding into the lumen of the early
Golgi compartment (Westerbeck & Machamer, 2019).
Alanine-scanning mutagenesis studies of the extramembrane
domain of E have shown that certain mutations impair viral
assembly and maturation, i.e. morphogenesis of MHV virions
(Fischer et al., 1998; Siu et al., 2008). Although according to
some authors (Venkatagopalan et al., 2015) E does not traffic
to the cell surface, avian IBV E protein interacts physically
with the M protein and is able to retain M in the compartment
that it resides in (Lim et al., 2001). In SARS-CoV this inter-
action is postulated to take place through the hydrophobic TM
domains (Chen et al., 2009). Propagation and shedding of
SARS-CoV virus-like particles requires the co-expression of E
and N proteins together with the M protein (Siu et al., 2008).
In addition to these roles in the assembly, trafficking and
shedding of virions, the E protein is also involved in the
stimulation of the immune response in the infected organism.
The evolutionary conservation of the E protein among CoVs
(Cao et al., 2020) makes it an interesting candidate for vaccine
development, and therefore knowledge of its surface epitopes
is of biological and biotechnological importance. A step in this
direction is the tentative mapping of the surface epitopes of
the SARS-CoV-2 E protein based on the structure from
SARS-CoV (Tilocca et al., 2020; Fig. 4). Polyclonal antibodies
that recognize the N-terminal 19 amino-acid residues of the
SARS-CoV E protein inhibit its ion-current ability (Wilson et
al., 2004).
Ion-channel activity resulting from the expression of CoV
viroporins induces stress responses and activates pro-
inflammatory pathways, and can lead to cell death (Minakshi
et al., 2009). In vitro, expression of the SARS-CoV orf3a
protein in the pulmonary epithelial cell line A549 upregulates
the expression of intracellular and secreted levels of the three
subunits of fibrinogen (Tan et al., 2005). Infection of Vero E6
cells with SARS-CoV leads to apoptosis, which in turn triggers
a virus-initiated cytopathic effect (Yan et al., 2004). Other
pathogenic changes include rearrangement of the membrane
(accumulation of intracellular vesicles), Golgi fragmentation
and cell death induced by SARS-CoV orf3a, which is reduced
upon deletion of orf3a (Freundt et al., 2010). The virus also
downregulates the inositol-requiring enzyme 1 (IRE-1)
signalling pathway in the unfolded protein response (DeDiego
et al., 2011). Most recently, the orf3a protein of SARS-CoV-2
has also been shown to induce apoptosis in various cell lines in
vitro. The apoptotic process involves the activity of caspase-8,
i.e. following the so-called extrinsic pathway, which induces
the release of mitochondrial cytochrome c and caspase-9
activation; the levels of apoptosis were, however, lower than
those induced in Vero E6 cells by SARS-CoV (Ren et al.,
2020).
Another expression of the pathogenic effects induced by
the SARS-CoV E protein is the increase in permeability of
the ERGIC/Golgi membrane, leading to the cytosolic
release of Ca2+ with concomitant activation of the NLRP3
inflammasome and induction of interleukin 1 (IL-1)
production (Nieto-Torres et al., 2015). When (+)RNA viruses
such as the CoVs utilize the host-cell ERGIC membranes to
reproduce their genomes, they modify this membrane complex
to produce a structurally different organelle: the replication
complex or replication organelle (Snijder et al., 2020). This
modified intermediate membrane compartment is character-
ized by the appearance of double-membrane vesicles (DMVs)
250–300 nm in diameter where the double-stranded RNA is
copied into new (+)RNA genomes (Fig. 5). How is the
nascent genomic (+)RNA released from inside the DMVs
into the cytosol? A recent cryo-EM tomography study of
cells infected with SARS-CoV-2 and other CoVs such as
MHV identified a pore traversing the two adjacent lipid
bilayers of the DMVs. The pore is formed by six copies of
the nonstructural protein nsp3 essential for viral replication
(Wolff et al., 2020).
Analogous structures called necked spherules can be
observed in cells infected with other (+)RNA viruses such as
Zika virus (a flavivirus), Chikungunya virus (an alphavirus)
and nodaviruses. In the latter case, RNA-replication organ-
elles were imaged by cryo-EM tomography in the outer
mitochondrial membrane opening towards the cell cytoplasm.
The spherule neck appears as a ring containing 12 copies of
the nodavirus RNA-replication protein A (Unchwaniwala et
al., 2020).
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CoV pathogenesis is intimately related to the ability of the
infective viruses to hijack the various molecular effectors
required to bind to and enter the host cell, replicate their
RNA, assemble and be released from the host cell. Viral
assembly and intracellular migration is tightly coupled to the
ERGIC cellular machinery and its vesicle-mediated transport.
Expression of the E protein from avian IBV has recently been
discovered to induce neutralization of the Golgi pH, altering
the secretory pathway through interaction with host-cell
factors, thereby protecting the IBV spike protein S from
premature cleavage and increasing the
efficacy of infective virion release from
the cell (Westerbeck & Machamer,
2019).
Successful expression of the E
protein thus appears to be an essential
requisite for pathogenesis; in fact, atte-
nuated SARS-CoV virions lacking E
proteins have been suggested as vaccine
candidates (Netland et al., 2010).
Viruses lacking both E and orf3a are not
viable, and full-length E and orf3a
proteins are required for maximal
SARS-CoV replication and virulence.
In contrast, the viroporin orf8a has only
a minor impact on these activities
(Castaño-Rodriguez et al., 2018).
E-protein-mediated channel activity
has been correlated with enhanced
pulmonary damage following accumu-
lation of liquid and electrolytes in
pulmonary oedema observed in SARS,
driven by the inflammasome NLRP3
and IL-1 overexpression (Nieto-Torres
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Figure 5
CoV-induced DMVs revealed by cryo-EM tomography. (a) Tomographic slice (7 nm thick) of a cryo-lamella milled through an MHV-infected cell at a
middle stage of infection. (b) 3D model of the tomogram, with the segmented content annotated. ERGIC, ER-to-Golgi intermediate compartment.
Reproduced from Fig. 1 of Wolff et al. (2020) with permission from the publisher under the Creative Commons Attribution licence (https://
creativecommons.org/licenses/by/4.0).
Figure 4
Putative surface epitopes of the SARS-CoV and SARS-CoV-2 E proteins. (a) Model of the
homopentameric SARS-CoV E protein (PDB entry 5x29). Selected epitope sequences are mapped
in each monomer as displayed in (b). Epitope sequences are coloured as follows: blue,
LIVNSVLLFLAFVVFLLVTLAILTALRLCAY; cyan, LLVTLAILTALRLCA; green, LTALR-
LCAY; olive green, CNIVNVSLVKPSFYV; red, SLVKPSFYV; orange, LVKPSFYVYSRVKNL;
yellow, LVKPSFYVY; magenta, KPSFYVYSRVKNLNS. Reproduced from Figs. 2(a) and 2(b) of
Tilocca et al. (2020) with permission from Elsevier Masson SAS under the Creative Commons
Attribution licence (https://creativecommons.org/licenses/by/4.0).
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et al., 2015). Porcine reproductive and respiratory syndrome
virus infection also involves inflammasomes and IL-1-
induced inflammation and injury (Zhang et al., 2013). This
pathology could be related to disruption of the epithelial
apicobasal integrity in alveolar cells. In fact, SARS-CoV E
protein has been shown to interact with PALS1, a tight-
junction-associated protein in mammalian cells (Teoh et al.,
2010). The interaction is mediated by a PDZ-binding motif at
the carboxy-terminus of E that binds to a PDZ domain in
PALS1. The authors speculate that SARS-CoV E hijacks
PALS1 through this mechanism, abrogating epithelial cell
differentiation, a phenomenon that could also occur in the
alveolar cells in the pulmonary affectation of SARS (Teoh et
al., 2010) or SARS-CoV-2. In the case of MHV, expression of
E results in cellular apoptosis (Maeda et al., 2001). The PDZ-
binding motif in E, which is also present in the orf3a channel-
forming protein, lends it the capacity to bind to more than 400
target proteins in the infected host cells (Castaño-Rodriguez et
al., 2018), thus giving these viroporins sufficient versatility to
perturb multiple aspects of normal cell function.
The E protein is probably involved in the neurotropism of
CoVs. The human CoV HCoV-OC43 requires full expression
of its E protein for efficient replication and propagation in
neuronal cells in culture and for neurovirulence in the central
nervous system (Stodola et al., 2018).
8. Therapeutic potential of channel blockers acting on
CoV ion channels
The COVID-19 pandemic has given new impetus to research
on the E proteins of Betacoronavirus, the genus to which
SARS-CoV-2 belongs. A genomic analysis of the entire
database of betacoronaviruses showed that the gene coding
for the E protein is segregated into three different clusters,
one of which includes only SARS-CoV, SARS-CoV-2 and two
bat CoVs. SARS-CoV-2 E and the two bat CoVs are 100%
identical, whereas E from SARS-CoV and SARS-CoV-2
shows 95% homology (Alam et al., 2020). The five C-termini of
the homopentamer protrude into the cytoplasmic compart-
ment, where three point mutations (The55Ser, Val56Phe and
Glu69Arg) and a deletion (Gly70) mark the difference
between the latter two viruses. The extremes of the C-terminal
regions also harbour the loci of the key tetrapeptide segment
(DLLV) involved in PDZ-domain recognition (Alam et al.,
2020).
The ion-channel function of the SARS-CoV-2 E protein has
recently been explored experimentally in bacteria using three
indirect assays of channel activity: growth deficiency upon
overexpression, growth recovery in a K+ uptake-deficient
E. coli strain and cytoplasmic acidification in acidic growth
media (Singh Tomar & Arkin, 2020). Exploring a library of
repurposed drugs, these authors find that glicazide, which is of
therapeutic application in type-2 diabetes mellitus, apparently
blocks channel activity, as does the drug memantine.
Memantine is a low-affinity, voltage-dependent, noncompeti-
tive antagonist of the glutamatergic NMDA receptor, the
5-HT3 receptor and the 7 nicotinic acetylcholine receptor,
which are three members of the pentameric ligand-gated ion
channels (pLGICs), and is also an agonist of the dopamine D2
receptor. Memantine is used as a drug in Alzheimer’s disease,
with its therapeutic ability apparently residing in its channel-
blocking activity. Using a prokaryotic model system, the
proton- and GABA-gated pentameric ion-channel protein
GLIC from the bacterium Gloeobacter violaceus, Ulens and
coworkers showed that memantine blocks channel activity by
obstructing the channel vestibule facing the extracellular
milieu (Ulens et al., 2014).
The drug 5-(N,N-hexamethylene)amiloride has been shown
to block the SARS-CoV E protein channel in a manner similar
to the mechanism operating on the HIV-1 Vpu channel
(Wilson et al., 2006). Other viroporins, albeit from non-CoV
viruses, have also been found to be potential targets of
blocking compounds that interfere with the assembly and
release of mature virions (Behmard et al., 2018).
Second to the large superfamily of G-protein coupled
receptors (GPCRs), ion channels are among the most sought-
after membrane-protein targets by the United States Federal
Drug Administration. Ion-channel modulators in particular
have shown therapeutic potential and successes, for example
as blockers of influenza M2 channels (Moorthy et al., 2014;
Sakai et al., 2018; Niu et al., 2019). It is expected that the
current pandemic will prompt further research into this
important area, with obvious therapeutic opportunities.
9. Viral ion-channel proteins, lipid domains and
evolution
As analysed in the preceding section, several drugs with
pharmacological activity as ion-channel blockers also inhibit
ion fluxes mediated by viral ion-channel proteins. Here, I
speculate on other possible common features between the two
types of channels. It is estimated that about 4000 million years
ago planet Earth witnessed the appearance of protein mole-
cules with the capacity to selectively permeate ions through
the plasma membranes of prokaryotic organisms such as the
cyanobacterium G. violaceus or the bacillus Erwinia chry-
santhemi. Comparison of the crystal structures of these
proteins in prokaryotes and their homologs in eukaryotes has
led to the notion that they belong to the same superfamily of
pLGICs (Tasneem et al., 2004) that share a high degree of
structural homology and phylogenetic conservation (Barrantes,
2015). Furthermore, scrutiny of the ion-channel protein
phylogeny disclosed interesting points of contact with the
evolution of the machineries involved in lipid and, in parti-
cular, sterol biosynthesis. This observation led to the proposal
of the possible co-evolution of the hopanoids (sterol surro-
gates) with ion channels in prokaryotes and the appearance of
sterols with ion-channel proteins of eukaryotes (Barrantes &
Fantini, 2016).
The timing of the appearance of viruses is still a contro-
versial issue. Some evolutionists contend that viruses
originated from ‘ancient’ cells that existed before the last
universal cellular (common) ancestor (LUCA) gave rise to
modern cells, i.e. to the three superkingdoms of Archaea,
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Bacteria and Eukarya (Forterre, 2005), from ancient RNA
cells that predated the LUCA (Nasir et al., 2020). In contrast,
other theories support the idea that viruses evolved by
recombinational reassortment of genes in a co-evolutionary
process with cells rather than being ancestral to them
(Hendrix et al., 2000; Adachi et al., 2020; Cui et al., 2019). A
third line of thought conveys the idea that viruses stem from
cells via a process of reductive evolution, as hypothesized for
giant DNA viruses (Koonin & Yutin, 2018). In the case of
invertebrate viruses, co-evolution is supported by the large-
effect polymorphisms for host resistance and viral evasion,
which may have been favoured by virus-mediated selection
(Obbard & Dudas, 2014).
Against this backdrop, an intriguing question is whether the
cross-talk between channel-protein motifs and microenviron-
mental lipids observed in higher cells also occurs in viral
ion-channel proteins. Indeed, the envelope lipid bilayer of
influenza virus type A harbours cholesterol-rich, ordered lipid
domains (‘lipid rafts’; To & Torres, 2019), the characteristic
lateral heterogeneities that are employed by eukaryotic cells
as signalling platforms. Moreover, the cytoplasmic tail of
influenza virus M2 binds human annexin A6, a Ca2+/lipid-
scaffold protein that interacts with ordered lipid domains and
regulates the homeostatic equilibrium of cholesterol, while it
negatively modulates viral infection (Ma et al., 2012). Simi-
larly, a short linear motif in the cytoplasmic tail of influenza A
M2 establishes interactions with another constitutive ordered
lipid domain-resident protein, the cholesterol-binding protein
caveolin-1; inhibition of caveolin-1 expression diminishes
H1N1 influenza viral titres by hindering virus replication (Sun
et al., 2010). These may represent examples of molecular
mimicry, where the virus appropriates cellular elements that
enable it to interact with other endogenous partners of the
host cell that are normally involved in physiological mechan-
isms, for example, facilitating biogenesis, membrane associa-
tion or trafficking of the virus, among multiple other processes.
In the case of CoVs, lipid domains have been reported to
serve as entry sites for SARS-CoV in Vero E6 cells (Lu et al.,
2008), possibly due to the enrichment of its receptor, ACE2, in
these platforms; cholesterol depletion of ACE2-expressing
cells by acute treatment with methyl--cyclodextrin reduced
the binding of the S protein by 50% (Glende et al., 2008). The
alpha- and betacoronaviruses infect only mammals (Yu et al.,
2020) and may have appeared as variants of bat coronaviruses
much more recently in evolutionary terms (Letko et al., 2018;
Cui et al., 2019). All CoVs having orf3a structural homologs
evolved from the bat gene pool, whereas all those without
orf3a structural homologs derive from rodent, avian or pig
gene pools (Kern et al., 2020), suggesting co-evolution of the
ion-channel protein orf3a in CoVs whose reservoir is the bat.
Another interesting case is provided by the similar structure
and pharmacological sensitivity of the two pentameric viral
ion channels orf8a and E and the proton- and GABA-sensitive
prokaryotic channel GLIC. The pentameric bundle formed by
the first 22 residues of the 39-amino-acid-long SARS-CoV
orf8a (Chen et al., 2011) provides a structural framework on
which to model the homologous pentameric M2 helical array
of the bacterial GLIC protein from the cyanobacterium
G. violaceus (Hsu et al., 2015), a representative member of the
superfamily of pGLICs (Nys et al., 2013). Both orf8a and
GLIC permeate chloride ions, and the chloride flux is voltage-
sensitive (Hsu et al., 2015). More remarkably, the GLIC
prokaryotic ion channel is blocked by memantine (Ulens et al.,
2014), the same drug recently shown to inhibit the ion-channel
function of the SARS-CoV-2 E protein (Singh Tomar &
Arkin, 2020). Thus, the reported lack of homology between
viral and prokaryotic/eukaryotic ion channels (McClenaghan
et al., 2020) may relate only to their primary sequence; their
folding in space may provide the required 3D structure to
constitute a binding site for small organic molecules acting as
inhibitory drugs.
Knowledge of the phylogenetic kindredness between ion-
channel proteins of human pathogenic viruses and those of
animal reservoirs may contribute not only to our under-
standing of the biology of the virus ion channels per se, but
also to the development of therapeutic strategies to combat
them. There are still many open avenues that could contribute
to these endeavours and thus help to prevent future
pandemics. Understanding the mechanisms of coronavirus ion
channels is among these opportunities.
10. Future directions in viral ion-channel research
During recent months, structural biology has made an
unparalleled contribution to our understanding of the current
pandemic. Biophysical approaches, exploiting previous
methodological knowhow and information accrued over the
last two decades on other CoVs, have produced new detailed
data on the components of SARS-CoV-2 (Barrantes, 2021).
These help to shed light on the mechanisms involved in viral
recognition by host-cell receptors and possible interventions
to hinder this and other steps of the infective cycle of the virus.
In comparison with the massive amount of data accrued on the
S glycoprotein, viral ion-channel proteins are still relatively
unexplored from both the purely structural and mechanistic
points of view. New structural data are needed to understand
how viruses can alter the morphology of cellular components,
modify the secretory vesicle transport system to subserve viral
RNA replication, protect the spike protein from premature
cleavage and efficiently assemble it into new virions through
interaction with hijacked host-cell factors. A wide spectrum
of techniques, in particular the powerful cryo-EM, cryo-
tomography and super-resolution optical microscopies, offer
new possibilities to investigate viral ion channels with unpre-
cedented resolution: atomic level in the case of cryo-EM and
nanometric level (the mesoscale) in the case of live specimen
studies with optical nanoscopy (Barrantes, 2021).
In addition, the very nature of viral ion channels makes it
inherently possible to apply a bifrontal approach combining
the strengths of the structural cryo-imaging biophysical tech-
niques (for example serial cryo-focused ion beam/scanning
EM volume imaging) with single-molecule electrophysiology,
in the form of single-channel patch-clamp recording of
subcellular organelles, to characterize the structure–function
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correlations that are still missing in order to understand the
pathogenic effects of CoVs on cellular function.
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Nava, J. A., Álvarez, E., Oliveros, J. C., Zhao, J., Fett, C., Perlman,
S. & Enjuanes, L. (2011). PLoS Pathog. 7, e1002315.
Dı́az, J. (2020). Front. Physiol. 11, 870.
Estola, T. (1970). Avian Dis. 14, 330–336.
Fischer, F., Stegen, C. F., Masters, P. S. & Samsonoff, W. A. (1998). J.
Virol. 72, 7885–7894.
Fischer, W. B. & Hsu, H.-J. (2011). Biochim. Biophys. Acta, 1808, 561–
571.
Forterre, P. (2005). Biochimie, 87, 793–803.
Freundt, E. C., Yu, L., Goldsmith, C. S., Welsh, S., Cheng, A., Yount,
B., Liu, W., Frieman, M. B., Buchholz, U. J., Screaton, G. R.,
Lippincott-Schwartz, J., Zaki, S. R., Xu, X.-N., Baric, R. S.,
Subbarao, K. & Lenardo, M. J. (2010). J. Virol. 84, 1097–1109.
Fung, T. S. & Liu, D. X. (2019). Annu. Rev. Microbiol. 73, 529–557.
Glende, J., Schwegmann-Wessels, C., Al-Falah, M., Pfefferle, S., Qu,
X., Deng, H., Drosten, C., Naim, H. Y. & Herrler, G. (2008).
Virology, 381, 215–221.
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Wu, Q., Zhang, Y., Lü, H., Wang, J., He, X., Liu, Y., Ye, C., Lin, W.,
Hu, J., Ji, J., Xu, J., Ye, J., Hu, Y., Chen, W., Li, S., Wang, J., Wang, J.,
Bi, S. & Yang, H. (2003). Genomics Proteomics Bioinformatics, 1,
131–144.
Yan, H., Xiao, G., Zhang, J., Hu, Y., Yuan, F., Cole, D. K., Zheng, C. &
Gao, G. F. (2004). J. Med. Virol. 73, 323–331.
Ye, Y. & Hogue, B. G. (2007). J. Virol. 81, 3597–3607.
Yu, J., Qiao, S., Guo, R. & Wang, X. (2020). Nat. Commun. 11, 3070.
Zhang, K., Hou, Q., Zhong, Z., Li, X., Chen, H., Li, W., Wen, J., Wang,
L., Liu, W. & Zhong, F. (2013). Virology, 442, 156–162.
Zhang, R., Wang, K., Lv, W., Yu, W., Xie, S., Xu, K., Schwarz, W.,
Xiong, S. & Sun, B. (2014). Biochim. Biophys. Acta, 1838, 1088–
1095.
topical reviews
402 Barrantes  Structural biology of coronavirus ion channels Acta Cryst. (2021). D77, 391–402
electronic reprint
